Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact Study To Be Published in European Urology and Urology Practice, Respectively

These Studies and Genomic Health's First Liquid Biopsy Study in Bladder Cancer To Be Presented at 2014 Society of Urologic Oncology Annual Meeting, December 3-5

REDWOOD CITY, Calif., Nov. 19, 2014 /PRNewswire/ -- Genomic Health, Inc. GHDX today announced multiple upcoming presentations at the 2014 Society of Urologic Oncology (SUO) Annual Meeting, including the second large, independent clinical validation study of the Oncotype DX® prostate cancer test and results from the first prostate cancer decision impact study.

The results from the latest validation study of the test, conducted in collaboration with the Center for Prostate Disease Research, have been accepted for publication in European Urology. Separately, the results of the first decision impact study of the Oncotype DX prostate cancer test, conducted in collaboration with academic and community practices at Columbia University, Delaware Valley Urology and Orange County Urology, have been accepted for publication in Urology Practice, an official journal of the American Urological Association.

Additionally, Genomic Health will present results from its first liquid biopsy study assessing multiple technologies, including next-generation sequencing, for their ability to detect and analyze the presence of bladder cancer in urine. These results represent important progress in the development of a proprietary liquid biopsy platform. This will be the company's first report of results from two early feasibility studies in liquid biopsy, with another upcoming presentation about the detection of breast cancer in blood scheduled for presentation at the 2014 Annual San Antonio Breast Cancer Symposium in December.

All SUO presentations will occur on Wednesday, December 3, 4:30 – 6:00 p.m. Eastern Time at Bethesda North Marriott Hotel & Conference Center in Rockville, Md. Additional details follow:

Poster #75: "A Biopsy-Based 17-gene Genomic Prostate Score Predicts Adverse Surgical Pathology and Recurrence After Radical Prostatectomy in Men with Clinically Low and Intermediate-Risk Prostate Cancer."

Authors: Isabell Sesterhenn, Timothy Brand, Inger Rosner, Joel Moncur, Amina Ali, Yongmei Chen, Nan Zhang, Athanasios Tsiatis, Dejan Knezevic, Tara Maddala, H. Jeffrey Lawrence, Phillip Febbo, Shiv Srivastava, David McLeod and Jennifer Cullen

Poster #71: "The Impact of the Oncotype DX Genomic Prostate Score (GPS) on Initial Treatment Recommendations for Men with Newly Diagnosed Clinically Low-Risk Prostate Cancer."

Authors: Ketan Badani, Michael Kemeter, Phillip Febbo, H. Jeffrey Lawrence, Bela Denes, Megan Rothney, Michael Rothberg and Gordon Brown

Poster #5: "Next-Generation Sequencing of DNA from Urine Detects Multiple Bladder Tumor-Derived Alterations and Additional Changes that Suggest Tumor Heterogeneity."

Authors: Richard D. Abramson, Gregory E. Alexander, Ellen M. Beasley, Francois Collin, Michael Crager, Andrew Dei Rossi, Joseph Dorado, Adam Friedman, Bill Gibb, Jennie Jeong, Col Jones, Chin-Jen Ku, Yan Ma, John Morlan, Kunbin Qu, Aibing Rao, Aaron Scott, Haluk Tezcan, Neal Shore and Phillip G. Febbo

About Oncotype DX®

The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The Oncotype DX prostate cancer test identifies low- to intermediate-risk patients eligible for active surveillance, as well as those who may benefit from immediate invasive treatment by predicting disease aggressiveness. With half a million patients tested in more than 70 countries, the Oncotype DX testing has redefined personalized medicine by making genomics an indispensable part of cancer diagnosis and treatment. To learn more about Oncotype DX prostate cancer test, visit: www.OncotypeDX.com or www.myprostatecancertreatment.org.

About Genomic Health

Genomic Health, Inc. GHDX is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and benefits of its test, to physicians and patients; the attributes and focus of the company's product pipeline; the company's belief that it is applying its infrastructure and expertise to lead the translation of genomic data into clinically actionable results; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2014. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.